RU2011118522A - Выделяющие оксид азота соединения - Google Patents

Выделяющие оксид азота соединения Download PDF

Info

Publication number
RU2011118522A
RU2011118522A RU2011118522/15A RU2011118522A RU2011118522A RU 2011118522 A RU2011118522 A RU 2011118522A RU 2011118522/15 A RU2011118522/15 A RU 2011118522/15A RU 2011118522 A RU2011118522 A RU 2011118522A RU 2011118522 A RU2011118522 A RU 2011118522A
Authority
RU
Russia
Prior art keywords
nitric oxide
dystrophy
releasing compound
oxide releasing
treat
Prior art date
Application number
RU2011118522/15A
Other languages
English (en)
Other versions
RU2560144C2 (ru
Inventor
Эмилио КЛЕМЕНТИ (IT)
Эмилио КЛЕМЕНТИ
Джулио КОССУ (IT)
Джулио КОССУ
Сильвия БРУНЕЛЛИ (IT)
Сильвия БРУНЕЛЛИ
Эннио ОНГИНИ (IT)
Эннио Онгини
Original Assignee
Никокс С.А. (Fr)
Никокс С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Никокс С.А. (Fr), Никокс С.А. filed Critical Никокс С.А. (Fr)
Publication of RU2011118522A publication Critical patent/RU2011118522A/ru
Application granted granted Critical
Publication of RU2560144C2 publication Critical patent/RU2560144C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1. Высвобождающее оксид азота соединение формулы (Iа) !M-X-Y-ONO2 (Ia) ! применяемое для лечения мышечных дистрофий, где в общей формуле (Iа) М, Х и Y имеют следующие значения: ! М - остаток: ! ! Х представляет -O-, ! Y представляет прямой или разветвленный С1-C20 алкилен. ! 2. Высвобождающее оксид азота соединение по п.1, где Y представляет прямой или разветвленный C1-С10 алкилен, применяемое для лечения мышечных дистрофий. ! 3. Высвобождающее оксид азота соединение по п.1 или 2, применяемое для лечения дистрофии Дюшенна или дистрофии Беккера.

Claims (3)

1. Высвобождающее оксид азота соединение формулы (Iа)
M-X-Y-ONO2 (Ia)
применяемое для лечения мышечных дистрофий, где в общей формуле (Iа) М, Х и Y имеют следующие значения:
М - остаток:
Figure 00000001
Х представляет -O-,
Y представляет прямой или разветвленный С1-C20 алкилен.
2. Высвобождающее оксид азота соединение по п.1, где Y представляет прямой или разветвленный C1-С10 алкилен, применяемое для лечения мышечных дистрофий.
3. Высвобождающее оксид азота соединение по п.1 или 2, применяемое для лечения дистрофии Дюшенна или дистрофии Беккера.
RU2011118522/04A 2006-02-03 2007-01-23 Выделяющие оксид азота соединения RU2560144C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76475506P 2006-02-03 2006-02-03
US60/764.755 2006-02-03

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2008135153/15A Division RU2429828C2 (ru) 2006-02-03 2007-01-23 Применение нитрооксипроизводного лекарственного средства для лечения мышечной дистрофии

Publications (2)

Publication Number Publication Date
RU2011118522A true RU2011118522A (ru) 2012-11-20
RU2560144C2 RU2560144C2 (ru) 2015-08-20

Family

ID=38004694

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2008135153/15A RU2429828C2 (ru) 2006-02-03 2007-01-23 Применение нитрооксипроизводного лекарственного средства для лечения мышечной дистрофии
RU2011118522/04A RU2560144C2 (ru) 2006-02-03 2007-01-23 Выделяющие оксид азота соединения

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2008135153/15A RU2429828C2 (ru) 2006-02-03 2007-01-23 Применение нитрооксипроизводного лекарственного средства для лечения мышечной дистрофии

Country Status (18)

Country Link
US (1) US8575222B2 (ru)
EP (2) EP2786749A1 (ru)
JP (1) JP5745210B2 (ru)
KR (1) KR20080097989A (ru)
CN (1) CN101378739B (ru)
AU (1) AU2007211508B2 (ru)
CA (1) CA2641816C (ru)
DK (1) DK1978947T3 (ru)
ES (1) ES2520893T3 (ru)
HK (1) HK1129592A1 (ru)
IL (1) IL192299A0 (ru)
NZ (1) NZ569396A (ru)
PL (1) PL1978947T3 (ru)
PT (1) PT1978947E (ru)
RU (2) RU2429828C2 (ru)
SI (1) SI1978947T1 (ru)
WO (1) WO2007088123A2 (ru)
ZA (1) ZA200805716B (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2912259C (en) 2005-05-27 2020-04-28 Mark H. Schoenfisch Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US9155758B2 (en) 2006-08-01 2015-10-13 Phrixus Pharmaceuticals, Inc. Treatment of chronic progressive heart failure
KR20090128423A (ko) * 2007-04-13 2009-12-15 니콕스 에스. 에이. 아토르바스타틴 4-(니트록시)부틸 에스테르의 결정형
MX2010006698A (es) 2007-12-17 2010-12-06 Univ Michigan Composiciones y metodos para el tratamiento y prevención de deficiencias del musculo esqueletico.
WO2009121623A2 (en) * 2008-04-04 2009-10-08 Summit Corporation Plc Compounds for treating muscular dystrophy
WO2010108843A1 (en) 2009-03-27 2010-09-30 Nicox S.A. Use of nitrooxyderivative of paracetamol for the treatment of muscular dystrophies
DK2467173T3 (da) 2009-08-21 2019-07-29 Novan Inc Sårbandager, fremgangsmåder til anvendelse heraf og fremgangsmåder til dannelse deraf
EP4249001A3 (en) 2009-08-21 2023-11-29 Novan, Inc. Topical gels
US9023890B2 (en) 2009-12-02 2015-05-05 The Charlotte-Mecklenburg Hospital Authority Nitrate esters and their use for the treatment of muscle and muscle related diseases
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
EP2681286B1 (en) 2011-02-28 2018-08-15 Novan, Inc. Nitric oxide-releasing s-nitrosothiol-modified silica particles and methods of making the same
US9452117B2 (en) 2011-06-01 2016-09-27 The Charlotte-Mecklenburg Hospital Authority Nitrate esters and their use for the treatment of muscle and muscle related diseases
WO2014111957A1 (en) 2013-01-21 2014-07-24 Apparao Satyam Nitric oxide releasing prodrugs of therapeutic agents
RU2517259C1 (ru) * 2013-03-06 2014-05-27 Федеральное государственное бюджетное учреждение науки Государственный научный центр Российской Федерации - Институт медико-биологических проблем Российской академии наук (ГНЦ РФ-ИМБП РАН) Способ профилактики и снижения деструкции белков скелетных мышц при их атрофии, вызванной гипокинезией и/или гравитационной разгрузкой
WO2014169976A1 (en) * 2013-04-18 2014-10-23 Nicox Science Ireland Quinone based nitric oxide donating compounds
US9974767B2 (en) 2014-07-14 2018-05-22 University Of Washington Statins in the treatment of muscular dystrophies and myopathies
KR101661332B1 (ko) 2015-05-28 2016-09-29 (의료)길의료재단 글루카곤 유사 펩타이드-1 수용체 항진제를 포함하는 근감소증 치료용 약학 조성물
US10993993B2 (en) 2015-05-28 2021-05-04 Immunoforge Co., Ltd. Pharmaceutical composition for treating muscle atrophy or sarcopenia including glucagon-like peptide (GLP-1) or GLP-1 receptor agonist
DK3483164T3 (da) 2017-03-20 2020-03-23 Forma Therapeutics Inc Pyrrolopyrrolsammensætninger som pyruvatkinase (pkr) aktivatorer
KR102204204B1 (ko) 2018-04-25 2021-01-18 주식회사 온코크로스 근육 질환 예방 및 치료용 조성물
US20220031671A1 (en) 2018-09-19 2022-02-03 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
US20230055923A1 (en) 2018-09-19 2023-02-23 Forma Therapeutics, Inc. Activating pyruvate kinase r
KR102272616B1 (ko) 2021-03-25 2021-07-05 주식회사 엔테로바이옴 피컬리박테리움 프로스니치 균주를 포함하는 근위축증 예방 또는 치료용 약학적 조성물
KR102329853B1 (ko) 2021-03-25 2021-11-23 주식회사 엔테로바이옴 아커만시아 뮤시니필라 균주를 포함하는 근위축증 예방 또는 치료용 약학적 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100387359B1 (ko) 1994-05-10 2003-08-27 니콕스 에스. 에이. 항-염증성,비알러지성및항-혈전성을가지는니트로화합물들과그들의조성물들
US5583101A (en) * 1994-07-15 1996-12-10 Harvard College Use of nitrogen oxide species and adducts to inhibit skeletal muscle contraction
IT1288123B1 (it) * 1996-09-04 1998-09-10 Nicox Sa Uso di nitroderivati per l'incontinenza urinaria
CA2371927A1 (en) * 1999-03-11 2000-09-14 The University Of Manitoba Nitric oxide manipulation of muscle satellite cell activation
FR2794647A1 (fr) * 1999-06-11 2000-12-15 Centre Nat Rech Scient Compositions pharmaceutique comprenant du no ou au moins un compose capable de liberer ou d'induire la formation de no dans les cellules
ITMI991517A1 (it) 1999-07-09 2001-01-09 Nicox Sa Procedimento per ottenere nitrossimetil fenil esterni di derivati dell'acido salicilico
IT1313596B1 (it) * 1999-08-04 2002-09-09 Nicox Sa Processo per la preparazione di nitrossialchil esteri del naproxene
ITMI20011744A1 (it) * 2001-08-09 2003-02-09 Nicox Sa Farmaci per le vasculopatie
ITMI20021392A1 (it) * 2002-06-25 2003-12-29 Nicox Sa Forme farmaceutiche per la somministrazione orale di farmaci liquidi a temperatura ambiente dotate di migliore biodisponibilita'
US7166638B2 (en) * 2003-05-27 2007-01-23 Nicox S.A. Statin derivatives
US20050113409A1 (en) * 2003-09-03 2005-05-26 Pharmacia Corporation Method for the prevention or treatment of pain, inflammation and inflammation-related disorders with a Cox-2 selective inhibitor in combination with a nitric oxide-donating agent and compositions therewith
GB0321228D0 (en) * 2003-09-10 2003-10-08 Inpharmatica Ltd Modulating cell activity
CA2820200C (en) * 2005-06-09 2015-08-18 Judith Esther Anderson Compositions and methods for enhancing nitric oxide delivery
CA2641815C (en) 2006-02-03 2015-06-09 Giulio Cossu Method of treatment for muscular dystrophy

Also Published As

Publication number Publication date
AU2007211508B2 (en) 2012-08-23
CA2641816A1 (en) 2007-08-09
RU2008135153A (ru) 2010-03-10
AU2007211508A1 (en) 2007-08-09
RU2560144C2 (ru) 2015-08-20
WO2007088123A2 (en) 2007-08-09
US20090093510A1 (en) 2009-04-09
EP2786749A1 (en) 2014-10-08
EP1978947B1 (en) 2014-08-13
DK1978947T3 (da) 2014-11-03
WO2007088123A3 (en) 2007-09-20
JP2009525302A (ja) 2009-07-09
PT1978947E (pt) 2014-11-03
EP1978947A2 (en) 2008-10-15
ZA200805716B (en) 2009-11-25
CN101378739B (zh) 2014-06-04
CN101378739A (zh) 2009-03-04
IL192299A0 (en) 2009-08-03
HK1129592A1 (en) 2009-12-04
ES2520893T3 (es) 2014-11-12
CA2641816C (en) 2016-01-05
JP5745210B2 (ja) 2015-07-08
US8575222B2 (en) 2013-11-05
PL1978947T3 (pl) 2015-03-31
RU2429828C2 (ru) 2011-09-27
NZ569396A (en) 2011-06-30
SI1978947T1 (sl) 2014-12-31
KR20080097989A (ko) 2008-11-06

Similar Documents

Publication Publication Date Title
RU2011118522A (ru) Выделяющие оксид азота соединения
RU2008139905A (ru) Фармацевтическая композиция для наружного применения
JP2010534247A5 (ru)
EP2443926A3 (en) Cyclopamine analogs
EP1946799A3 (en) Silicone copolymer and cosmetics comprising the same
RU2010107684A (ru) Конденсированные гетероциклы
JP2013515822A5 (ru)
BRPI0914103A2 (pt) utilização de um copolímero hidrossolúvel ou álcali-solúvel
JP2008506697A5 (ru)
RU2006135836A (ru) АНДРОГРАФОЛИД И АНАЛОГИ В КАЧЕСТВЕ ИНГИБИТОРОВ ЭКСПРЕССИИ TNFα И IL-1β
RU2008151868A (ru) Мономер для поликонденсации
EA201170015A1 (ru) Производные 2-оксоалкил-1-пиперазин-2-она, их получение и их применение в терапии
EA200901164A1 (ru) КОНДЕНСИРОВАННЫЕ ПИРИМИДИНОНЫ В КАЧЕСТВЕ ЛИГАНДОВ mGLUR
EA200901179A1 (ru) Замещённые тетрагидрохинолины
RU2009138470A (ru) Композиция для наружного применения на коже
JP2013512321A5 (ru)
RU2006108074A (ru) Ингибитор дифференцировки кроветворных клеток-предшественников
RU2008127672A (ru) Водорастворимые полимерные комплексы арбидола
EP1352901A3 (en) Process for the preparation of cyclic diketones
FR2923825B1 (fr) Nouveaux inhibiteurs du virus du papillome humain et les compositions pharmaceutiques les contenant.
RU2006144009A (ru) Бензиламид n-(2-фураноил)-5-йодантраниловой кислоты и диметиламид n-(2-фураноил)-5-йодантраниловой кислоты, проявляющие противовоспалительную активность
RU2012139286A (ru) Нестероидные противовоспалительные средства на основе производных пиридоксина
FI20065222A0 (fi) Inositolin käyttö
RU2005105766A (ru) Водно-глицериновый комплекс (2,3-диоксипропил)орто-титанат-силиката "кремнелайф" и фармацевтическая композиция на его основе
EP1958634A3 (en) Substituted piperidines as inhibitors of beta-secretase, cathepsin D, plasmepsin II and/or HIV protease

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant
PC41 Official registration of the transfer of exclusive right

Effective date: 20181229

MM4A The patent is invalid due to non-payment of fees

Effective date: 20200124